MeSH term
Frequency | Condition_Probility | Humans | 93 | 0.0 |
Acute Disease | 2 | 0.0 |
Animals | 36 | 0.0 |
Chronic Disease | 3 | 0.0 |
English Abstract | 8 | 0.0 |
Research Support, Non-U.S. Gov't | 46 | 0.0 |
Th2 Cells/*immunology | 4 | 3.0 |
Amino Acid Sequence | 12 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Molecular Sequence Data | 22 | 0.0 |
Protein Binding | 5 | 0.0 |
Protein Conformation | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 19 | 0.0 |
Signal Transduction | 4 | 0.0 |
Cell Division | 5 | 0.0 |
Cell Line | 13 | 0.0 |
Conserved Sequence | 2 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Mice | 16 | 0.0 |
Models, Molecular | 2 | 0.0 |
Mutagenesis | 2 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Mutation | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor/*chemistry | 2 | 100.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Adolescent | 6 | 0.0 |
Adult | 17 | 0.0 |
Aged | 5 | 0.0 |
Cytokines/blood | 3 | 1.0 |
Analysis of Variance | 2 | 0.0 |
Comparative Study | 12 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
Female | 18 | 0.0 |
Male | 22 | 0.0 |
Middle Aged | 11 | 0.0 |
Reference Values | 2 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Interleukins/genetics/metabolism | 2 | 33.0 |
Cytokines/*blood | 2 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
Cytokines/*genetics | 5 | 3.0 |
Exons/genetics | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/genetics | 2 | 7.0 |
Interleukin-13/genetics | 2 | 22.0 |
Interleukin-4/genetics | 5 | 12.0 |
Interleukin-5/genetics | 4 | 30.0 |
Mice/*genetics | 2 | 0.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Lymphocyte Activation/immunology | 2 | 0.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Mice, Inbred DBA | 2 | 0.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Phenotype | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
T-Lymphocytes/metabolism | 3 | 1.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Interleukin-5/*genetics | 5 | 41.0 |
T-Lymphocytes/*immunology | 5 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Base Sequence | 13 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Rats | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
T-Lymphocytes/immunology | 2 | 0.0 |
*Chemokines, CC | 2 | 2.0 |
Cytokines/physiology | 2 | 1.0 |
Interleukin-5/physiology | 4 | 40.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Leukocytes, Mononuclear/*metabolism | 2 | 1.0 |
In Vitro | 7 | 0.0 |
Interleukin-5/pharmacology | 2 | 7.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 2 | 0.0 |
Recombinant Proteins/pharmacology | 5 | 0.0 |
Brazil | 2 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Pedigree | 2 | 0.0 |
Interleukin-2/genetics | 3 | 3.0 |
Interleukins/*genetics | 2 | 7.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Child | 5 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Biological Markers | 3 | 0.0 |
Cell Division/drug effects | 3 | 0.0 |
Cells, Cultured | 8 | 0.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Eosinophil Peroxidase | 3 | 5.0 |
Eosinophils/*cytology | 2 | 15.0 |
Lipopolysaccharides/pharmacology | 3 | 0.0 |
Antigens/*immunology | 2 | 2.0 |
Clone Cells | 2 | 0.0 |
Cytokines/*immunology | 3 | 3.0 |
Prospective Studies | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Recombinant Proteins | 6 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Hypersensitivity/*immunology | 2 | 4.0 |
Interleukin-5/*biosynthesis | 3 | 30.0 |
Microscopy, Electron | 2 | 0.0 |
Calorimetry | 2 | 3.0 |
Interleukin-5/chemistry/*metabolism | 2 | 100.0 |
Receptors, Interleukin/chemistry/*metabolism | 2 | 22.0 |
Interleukin-3/physiology | 3 | 10.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/metabolism | 2 | 3.0 |
Interleukin-5/*metabolism | 2 | 25.0 |
Cell Differentiation | 4 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
T-Lymphocytes, Helper-Inducer/immunology | 2 | 1.0 |
CD4-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Gene Expression | 5 | 0.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Cell Survival | 2 | 0.0 |
Asthma/*immunology | 2 | 2.0 |
Cytokines/*biosynthesis | 3 | 0.0 |
Leukocyte Count | 3 | 0.0 |
Mites/immunology | 2 | 5.0 |
Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, Pair 5 | 5 | 2.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
Hybrid Cells | 3 | 0.0 |
Interleukin-4/*genetics | 5 | 10.0 |
Mice, Inbred C57BL | 2 | 0.0 |
*Receptors, Interleukin | 2 | 66.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Lymphocyte Activation | 3 | 0.0 |
Receptors, Interleukin-2/analysis | 2 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Antigens, CD/*analysis | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Interleukin-2/pharmacology | 4 | 0.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
Eosinophils/physiology | 3 | 23.0 |
Time Factors | 2 | 0.0 |
Immunoglobulin E/blood | 2 | 1.0 |
Cytokines/metabolism | 2 | 0.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Interleukin-4 | 5 | 5.0 |
Interleukin-5 | 6 | 46.0 |
Interleukin-6 | 2 | 4.0 |
Multivariate Analysis | 2 | 0.0 |
Principal Component Analysis | 2 | 9.0 |
Interleukins/*physiology | 2 | 6.0 |
Cytokines | 2 | 1.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Transfection | 2 | 0.0 |